MIST
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc. (MIST) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.8) | B+ (3.5) | C (2.4) | D (1.3) | C+ (2.6) | C+ (2.5) |
| 2026-11-06 | C+ (2.8) | B (3.5) | C (2.4) | D- (1.1) | C+ (2.7) | C (2.5) |
| 2026-10-30 | C+ (2.8) | B (3.5) | C (2.4) | D (1.4) | C+ (2.7) | C+ (2.5) |
| 2026-10-23 | C+ (2.8) | B (3.4) | C (2.4) | D- (1.1) | C+ (2.6) | C (2.5) |
| 2026-10-16 | C+ (2.8) | B (3.5) | C (2.4) | D (1.3) | C+ (2.6) | C (2.5) |